E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 3/29/2017 in the Prospect News Structured Products Daily.

New Issue: JPMorgan prices $520,000 review notes linked to health care fund, Russell

By Wendy Van Sickle

Columbus, Ohio, March 29 – JPMorgan Chase Financial Co. LLC priced $520,000 of 0% review notes due March 29, 2021 linked to the lesser performing of the Russell 2000 index and the Health Care Select Sector SPDR fund, according to a 424B2 filing with the Securities and Exchange Commission.

The notes are guaranteed by JPMorgan Chase & Co.

The notes will be called at par plus a premium of 10% a year if each underlier closes at or above its initial level on any annual review date.

The payout at maturity will be par plus 10% unless the final level of either underlier is less than its initial level by more than 30%, in which case investors will be fully exposed to the decline of the lesser-performing underlier.

J.P. Morgan Securities LLC is the agent.

Issuer:JPMorgan Chase Financial Co. LLC
Guarantor:JPMorgan Chase & Co.
Issue:Review notes
Underliers:Russell 2000 index and Health Care Select Sector SPDR fund
Amount:$520,000
Maturity:March 29, 2021
Coupon:0%
Price:Par
Payout at maturity:Par plus 10% unless final level of either underlier is less than initial level by more than 30%, in which case full exposure to decline of lesser-performing underlier
Call:Automatically at par plus premium of 10% a year if each underlier closes at or above initial level on any annual review date
Initial levels:1,354.642 for index and $74.29 for ETF
Pricing date:March 24
Settlement date:March 31
Agent:J.P. Morgan Securities LLC
Fees:2.4%
Cusip:46646QS55

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.